WO2017142294A1 - EGFRvIII에 대한 항체 및 이의 용도 - Google Patents
EGFRvIII에 대한 항체 및 이의 용도 Download PDFInfo
- Publication number
- WO2017142294A1 WO2017142294A1 PCT/KR2017/001623 KR2017001623W WO2017142294A1 WO 2017142294 A1 WO2017142294 A1 WO 2017142294A1 KR 2017001623 W KR2017001623 W KR 2017001623W WO 2017142294 A1 WO2017142294 A1 WO 2017142294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- egfrviii
- antigen
- cancer
- sequence
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Definitions
- the present invention provides an antibody to EGFRvIII (Epidermal Growth Factor Receptor Variant III) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, the antibody or an antigen-binding fragment thereof. It relates to a method, a composition for preventing or treating cancer, a composition for diagnosing cancer, and a kit for diagnosing cancer.
- antigen expressed on the cell surface of human cancer refers to a wide range of targets that are overexpressed or mutated and selectively expressed relative to normal tissue.
- the key problem is identifying the appropriate antigen for antibody-based therapies. These therapeutic agents mediate changes in antigen or receptor function (ie, as a stimulant or antagonist), regulate the immune system through Fc and T cell activation, and through the delivery of specific drugs that bind to antibodies targeting specific antigens. It is effective. Molecular techniques that can alter antibody pharmacokinetics, functional function, size and immune stimulation are emerging as key elements in the development of novel antibody-based therapies.
- Evidence from clinical trials of therapeutic antibodies in cancer patients is based on optimized antibodies, including affinity and binding of the target antigen and antibodies, selection of antibody structure, therapeutic approaches (blocking signaling or immune function). It highlights the importance of approaches for choice.
- EGFR epidermal growth factor receptor
- the sequence of the EGFR gene is known.
- the EGFR gene is a cell homologue of the erbB tumor gene originally identified in avian erythroblastosis virus. Activation of these tumor genes by gene amplification has been observed in various human tumors.
- EGFR is overexpressed against various types of human solid tumors. EGFR overexpression has been observed in some lung, breast, colon, stomach, brain, bladder, head and neck, ovary, kidney and prostate carcinomas. Epithelial growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) have been shown to bind to EGFR to induce cell proliferation and tumor growth. In addition, size variant EGFR genes and amplification have been reported in some human cancers.
- EGF epithelial growth factor
- TGF-alpha transforming growth factor-alpha
- EGFR variants are caused by gene rearrangements accompanied by EGFR gene amplification.
- EGFRvIII consists of 267 aa in-frame deletions in the extracellular domain of EGFR, (iv) EGFRvIV comprises a deletion in the cytoplasmic domain of EGFR, and (v) EGFRvV is EGFR A deletion in the cytoplasmic domain of (vi) EGFR.TDM / 2-7 comprises replication of exon 2-7 in the extracellular domain of EGFR, and (vii) EGFR.TDM / 18-25 is a cell of EGFR The exogenous domain includes replication of exon 18-26, and (viii) EGFR.TDM / 18-26 comprises replication of exon 18-26 to tyrosine kinase of EGFR. There is also a rare second EGFRvIII mutant (EGFRvIII / ⁇ 12-13) with a second deletion introducing a new histidine residue at the junction of exons 11 and 14.
- EGFRvIII is a variant of epidermal growth factor (EGF) most commonly occurring in human cancers, expressed in about 30% of glioblastoma (GBM) patients, but not in normal tissues.
- EGF epidermal growth factor
- GBM glioblastoma
- Mutations or rearrangements of genes that potentially induce tumor formation can be identified in many cancers. Results have been published that cancer-causing proteins can contribute to pathways associated with cancer stem cells. Evidence suggests that the product of these modified genes can be used to identify and potentially target cancer stem cells. Indeed, this approach is not an easy method because these major mutations exist throughout cancer cells and do not exist only in specific cancer cell subtypes. Thus mutant proteins generally dominate tumor growth without playing any direct role in cancer stem cells. In addition, most modified proteins are inside the cell.
- Glioblastoma tumors are known to frequently express EGFRvIII, an EGFR variant expressed through gene rearrangement and amplification. Since tyrosine phosphorylation sites are always present in an activated form, they exhibit strong tumorigenicity. However, despite this modification, the expression of EGFRvIII is limited.
- Cancer stem cells are defined as having high expression of EGFRvIII with CD133 and having high regeneration and tumor initiation ability of EGFRvIII + / CD133 + cells.
- EGFRvIII + cells are associated with stem / progenitor markers while differentiation markers were found in EGFRvIII- cells. EGFRvIII expression was lost in normal cell culture but maintained in tumor protoplast cultures and also cell cultured cells express and regenerate EGFRvIII + / CD133 + simultaneously and have tumor initiation capacity.
- anti-EGFRvIII antibodies are required that can bind to EGFRvIII with high affinity and inhibit the growth of cancer cells.
- Antibody therapeutics such as cetuximab and the like that specifically bind to conventional EGFR have been developed.
- these antibody therapies have a problem that the antigen specificity for EGFRvIII mutant cancer cells is very poor, and cancer cell growth inhibitory ability does not appear.
- the inventors of the present application have tried to develop an anti-cancer therapeutic antibody that specifically binds to EGFRvIII.
- the present inventors have developed an anti-EGFRvIII antibody that binds to EGFRvIII with high affinity using phage display technology, and confirmed that the antibody to such anti-EGFRvIII can significantly inhibit the migration of cancer cells. Completed.
- Another object of the present invention is to provide a nucleic acid encoding the antibody or antigen-binding fragment thereof.
- Another object of the present invention is to provide a vector comprising the nucleic acid, a cell transformed with the vector, and a method of manufacturing the same.
- Still another object of the present invention is to provide a composition for preventing or treating cancer comprising the antibody or antigen-binding fragment thereof.
- Still another object of the present invention is to provide a cancer diagnostic composition comprising the antibody or antigen-binding fragment thereof and a kit for cancer diagnosis comprising the same.
- the present invention is an antibody or antigen-binding fragment thereof that binds to Epidermal Growth Factor Receptor Variant III (EGFRvIII), wherein the antibody or antigen-binding fragment thereof binds to an epitope of EGFRvIII having a sequence of SEQ ID NO: 1
- EGFRvIII Epidermal Growth Factor Receptor Variant III
- the present invention also provides a nucleic acid encoding a heavy chain variable region of the antibody or antigen-binding fragment thereof.
- the present invention also provides a vector comprising the nucleic acid.
- the present invention also provides a cell transformed with the vector.
- the present invention also provides a method for producing the antibody or antigen-binding fragment thereof comprising the following steps: (a) culturing the cells; And (b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.
- the present invention also provides a composition for preventing or treating cancer, comprising the antibody or antigen-binding fragment thereof as an active ingredient.
- the present invention also provides a cancer diagnostic composition comprising the antibody or antigen-binding fragment thereof.
- the present invention further provides a kit for diagnosing cancer comprising the composition for diagnosing cancer.
- Figure 1 shows the result of confirming the mutation and expression of EGFRvIII of patient-derived cells by RT-PCR (Reverse Transcription Polymerase Chain Reaction) and western blot method.
- FIG. 2 shows a process for phage display screening of EGFRvIII specific scFv antibody fragments.
- FIG. 3 shows EGFRvIII antibody screening results and sequencing results using glioblastoma (GBM) patient cells.
- Figure 4 shows the results confirming the binding capacity of the B4A3 antibody and Cetuximab EGFRvIII specific peptide.
- Figure 5 shows the results confirming the binding capacity of the B4A3 antibody and Cetuximab EGFR recombinant protein.
- Figure 6 shows the results confirming the binding capacity of the B4A3 antibody and Cetuximab EGFRvIII recombinant protein.
- Figure 7 shows the results confirmed by SDS-PAGE EGFRvIII specific binding capacity of the B4A3 antibody and stained with the EGFR control antibody.
- Figure 8 shows the results of performing western blot to confirm the expression pattern of EGFR and EGFRvIII.
- Figure 9 shows the results of the FACS analysis to analyze the cell binding pattern of the anti-EGFRvIII scFv to EGFRvIII.
- Figure 10 shows the results confirming the binding pattern of the B4A3 antibody (IgG1) in normal cells.
- Figure 11 shows the results confirming the binding pattern of the B4A3 antibody (IgG1) in vIII352T1 expressing only EGFRvIII.
- Figure 12 shows the result of confirming that the binding of the saponin conjugated antibody to the B4A3 antibody, EGFRvIII-specific antibody-saporin conjugated antibody complex effectively internalizes and induces cytotoxicity in EGFRvIII-expressing patient cells.
- Figure 13 shows the results of quantification of the affinity of the B4A3 antibody.
- FIG. 14 shows vectors for preparing recombinant EGFR and EGFRvIII for quantification of affinity for EGFR and EGFRvIII of B4A3 antibodies.
- Figure 15 shows the results confirming the cancer cell growth inhibitory ability of B4A3 by In-vivo.
- the present invention provides an antibody or antigen-binding fragment thereof against EGFRvIII, wherein the antibody or antigen-binding fragment thereof binds to an epitope of EGFRvIII having a sequence of SEQ ID NO: 1. It is about.
- the present inventors have tried to develop an anti-cancer therapeutic antibody that binds to EGFRvIII, which is known to be expressed in various cancers. As a result, the present inventors prepared anti-EGFRvIII antibodies that bind to EGFRvIII with high affinity and internalize into cells using phage display technology, and confirmed that such anti-EGFRvIII antibodies can significantly inhibit the migration of cancer cells.
- EGFRvIII herein refers to a mutant type of epidermal growth factor receptor recognized by MR1 scFv and characterized by 801 base pair in-frame deletions of 2-7 exons near the amino terminus. It is highly expressed in about 50-60% of glioblastoma and appears to be present in about 70-80% of breast and ovarian carcinoma and about 16% of non-small cell lung carcinoma. Mutant receptors are expressed on the cell surface and produce new tumor specific cell surface epitopes at the deletion junctions.
- Epitope refers to a protein determinant to which an antibody can specifically bind.
- Epitopes usually consist of a group of chemically active surface molecules, such as amino acids or sugar side chains, and generally have specific three dimensional structural characteristics as well as specific charge characteristics. Three-dimensional epitopes and non-stereo epitopes are distinguished in that the binding to the former is lost but not to the latter in the presence of a denatured solvent.
- the present invention relates to an antibody or antigen binding fragment thereof that binds to an epitope of EGFRvIII having the sequence of SEQ ID NO: 1.
- antibody refers to an anti-EGFRvIII antibody that specifically binds to EGFRvIII.
- the scope of the present invention includes not only complete antibody forms that specifically bind EGFRvIII, but also antigen binding fragments of such antibody molecules.
- a complete antibody is a structure having two full length light chains and two full length heavy chains, each of which is linked by heavy and disulfide bonds.
- the heavy chain constant region has gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) and epsilon ( ⁇ ) types and subclasses gamma 1 ( ⁇ 1), gamma 2 ( ⁇ 2), and gamma 3 ( ⁇ 3). ), Gamma 4 ( ⁇ 4), alpha 1 ( ⁇ 1) and alpha 2 ( ⁇ 2).
- the constant regions of the light chains have kappa ( ⁇ ) and lambda ( ⁇ ) types.
- Antibodies of the invention include monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single chain Fvs (scFV), single chain antibodies, Fab fragments, F (ab ') fragments, disulfide-binding Fvs (sdFV) And anti-idiotype (anti-Id) antibodies, or epitope-binding fragments of the antibodies, and the like.
- An antigen binding fragment or antibody fragment of an antibody means a fragment having an antigen binding function and includes Fab, F (ab '), F (ab') 2, Fv and the like.
- Fab in the antibody fragment has a structure having a variable region of the light and heavy chains, a constant region of the light chain and the first constant region (CH1) of the heavy chain has one antigen binding site.
- F (ab ') 2 antibodies are produced by disulfide bonds of cysteine residues in the hinge region of Fab'.
- Double-chain Fv is a non-covalent bond in which a heavy chain variable region and a light chain variable region are linked, and a single chain Fv (single-chain Fv, scFv) is generally a variable region of the heavy chain and the light chain through a peptide linker.
- This covalent linkage or the C-terminus is directly linked to form a dimer-like structure such as a double-chain Fv.
- Such antibody fragments can be obtained using proteolytic enzymes (e.g., restriction digestion of the entire antibody with papain yields Fab and cleavage with pepsin yields F (ab ') 2 fragments). It can also be produced by recombinant technology.
- Fv fragments are antibody fragments containing complete antibody recognition and binding sites. This region consists of a dimer in which one heavy chain variable domain and one light chain variable domain are tightly and covalently associated, for example, with scFv.
- Fab fragments contain the variable and constant domains of the light chain and the variable and first constant domains (CH1) of the heavy chain.
- F (ab ') 2 antibody fragments generally comprise a pair of Fab fragments covalently linked near their carboxy termini by hinge cysteines between them.
- Single-chain Fv or “scFv” antibody fragments comprise the VH and VL domains of an antibody, which domains are present in a single polypeptide chain.
- the Fv polypeptide may further comprise a polypeptide linker between the VH domain and the VL domain that allows the scFv to form the desired structure for antigen binding.
- the antibody according to the invention is in Fv form (eg scFv) or is in the form of a complete antibody.
- the heavy chain constant region may be selected from any one isotype of gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) or epsilon ( ⁇ ).
- the constant region is gamma 1 (IgG1), gamma 3 (IgG3) or gamma 4 (IgG4).
- the light chain constant region may be of kappa or lambda type.
- the term “heavy chain” refers to a variable region domain VH comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen and a full length heavy chain comprising three constant region domains CH1, CH2 and CH3 And fragments thereof.
- the term “light chain” as used herein refers to a full-length light chain and fragment thereof comprising a variable region domain VL and a constant region domain CL comprising an amino acid sequence having sufficient variable region sequence to confer specificity to the antigen. All means.
- Said monoclonal antibody refers to the same except for possible naturally occurring mutations in which antibodies obtained from substantially homogeneous antibody populations, ie, individual antibodies in the population, may be present in trace amounts. Monoclonal antibodies are highly specific and are directed against a single antigenic site.
- Non-human (eg murine) antibodies of the “humanized” form are chimeric antibodies that contain minimal sequences derived from non-human immunoglobulins.
- humanized antibodies are non-human species (donor antibodies) that retain the desired specificity, affinity, and capacity for residues from the hypervariable region of the recipient, for example mice, rats, rabbits, or non-humans.
- donor antibodies non-human species
- Human immunoglobulins (receptor antibodies) replaced with residues from the hypervariable regions of primates.
- human antibody refers to a molecule derived from human immunoglobulin, in which all of the amino acid sequences constituting the antibody including complementarity determining regions and structural regions are composed of human immunoglobulins.
- While the heavy and / or light chain portions are the same or homologous to the corresponding sequences in an antibody derived from a particular species or belonging to a particular antibody class or subclass, the remaining chain (s) are derived from another species or another antibody class or Included are "chimeric" antibodies (immunoglobulins) that are identical or homologous to the corresponding sequences in antibodies belonging to the subclass, as well as fragments of such antibodies that exhibit the desired biological activity.
- antibody variable domain refers to the light and heavy chain portions of an antibody molecule comprising the amino acid sequences of complementarity determining regions (CDRs; ie CDR1, CDR2, and CDR3), and framework regions (FR). .
- CDRs complementarity determining regions
- FR framework regions
- VH refers to the variable domain of the heavy chain.
- VL refers to the variable domain of the light chain.
- CDRs Complementarity determining regions
- Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3.
- FRs Framework regions
- Each variable domain typically has four FRs identified as FR1, FR2, FR3 and FR4.
- the present invention provides an antibody or antigen-binding fragment thereof comprising the following heavy chain CDRs and light chain CDRs: complementarity determining region H1 having the sequence of SEQ ID NO: 2, sequence A heavy chain variable region comprising a CDRH2 having a sequence of SEQ ID NO: 3, and a CDRH3 having a sequence of SEQ ID NO: 4; And a light chain variable region comprising CDRL1 having a sequence of SEQ ID NO: 5, CDRL2 having a sequence of SEQ ID NO: 6, and CDRL3 having a sequence of SEQ ID NO.
- the antibody or antigen-binding fragment thereof of the invention may comprise a framework region (FR) having one or more sequences selected from the group consisting of SEQ ID NOs: 8 to 15, specifically SEQ ID NO:
- a heavy chain variable region including a heavy chain framework region (FR) having one sequence selected from the group consisting of the sequences of 8 to SEQ ID NO: 11 may be included.
- the heavy chain FR1 having the sequence of SEQ ID NO: 8 the heavy chain FR2 having the sequence of SEQ ID NO: 9, the heavy chain FR3 having the sequence of SEQ ID NO: 10, heavy chain FR4 having the sequence of SEQ ID NO: 11.
- the antibody or antigen-binding fragment thereof of the present invention may include a light chain variable region comprising a light chain FR having one sequence selected from the group consisting of SEQ ID NO: 12 to SEQ ID NO: 15.
- the light chain FR1 having the sequence of SEQ ID NO: 12 the light chain FR2 having the sequence of SEQ ID NO: 13, the light chain FR3 having the sequence of SEQ ID NO: 14, and the light chain FR4 having the sequence of SEQ ID NO: 15 may be included.
- the antibody or antigen-binding fragment thereof of the invention may comprise a heavy chain variable region having the sequence of SEQ ID NO: 16 and / or comprise a light chain variable region having the sequence of SEQ ID NO: 17.
- Phase display is a technique for displaying variant polypeptides as phage proteins, such as fusion proteins with at least a portion of the envelope protein on the surface of fibrous phage particles.
- the utility of phage display lies in the fact that a large library of randomized protein variants can be targeted to quickly and efficiently classify sequences that bind with high affinity with a target antigen. Displaying peptide and protein libraries on phage has been used to screen millions of polypeptides to identify polypeptides with specific binding properties.
- Phage display technology provided a powerful tool for generating and selecting new proteins that bind specific ligands (eg antigens). Phage display technology can be used to generate large libraries of protein variants and to quickly sort sequences that bind with high affinity to target antigens.
- Nucleic acids encoding variant polypeptides are fused with nucleic acid sequences encoding viral envelope proteins, eg, gene III protein or gene VIII protein.
- Monovalent phage display systems have been developed in which a nucleic acid sequence encoding a protein or polypeptide is fused with a nucleic acid sequence encoding a portion of a gene III protein. In monovalent phage display systems, gene fusions are expressed at low levels and wild type Gene III proteins are also expressed to maintain particle infectivity.
- Phage display technology has several advantages over conventional hybridoma and recombinant methods for preparing antibodies with the desired characteristics. This technique allows the production of large antibody libraries with various sequences in a short time without the use of animals. The preparation of hybridomas or the production of humanized antibodies may require months of preparation. In addition, since no immunity is required at all, phage antibody libraries can produce antibodies against antigens that are toxic or low antigenic. Phage antibody libraries can also be used to generate and identify novel therapeutic antibodies.
- Techniques for generating human antibodies from immunized, non-immunized human, germline sequences, or na ⁇ ve B cell Ig repertory using immunized phage display libraries can be used.
- Various lymphoid tissues can be used to prepare na ⁇ ve or non-immune antigen binding libraries.
- the ability to identify and isolate high affinity antibodies from phage display libraries is important for the isolation of novel therapeutic antibodies. Separation of high affinity antibodies from the library may depend on the size of the library, the efficiency of production in bacterial cells, and the diversity of the library.
- the size of the library is reduced by inefficient folding of the antibody or antigen binding protein and inefficient production due to the presence of stop codons. Expression in bacterial cells can be inhibited if the antibody or antigen binding domain is not properly folded. Expression can be improved by alternating mutations at the surface of the variable / constant interface or at selected CDR residues.
- the sequence of the backbone region is one element to provide proper folding when generating antibody phage libraries in bacterial cells.
- CDR3 regions have been found to often participate in antigen binding.
- the CDR3 regions on the heavy chains vary considerably in size, sequence, and structural conformation, and thus can be used to prepare a variety of libraries.
- diversity can be generated by randomizing the CDR regions of the variable heavy and light chains using all 20 amino acids at each position.
- the use of all twenty amino acids can result in highly variable variant antibody sequences and increase the chance of identifying new antibodies.
- Antibodies or antibody fragments of the present invention may include not only the sequences of the anti-EGFRvIII antibodies of the invention described herein, but also biological equivalents thereof, within the scope of specific recognition of EGFRvIII.
- further changes can be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody.
- Such modifications include, for example, deletions, insertions and / or substitutions of amino acid sequence residues of the antibody.
- Such amino acid variations are made based on the relative similarity of amino acid side chain substituents such as hydrophobicity, hydrophilicity, charge, size, and the like.
- arginine, lysine and histidine are all positively charged residues; Alanine, glycine and serine have similar sizes; It can be seen that phenylalanine, tryptophan and tyrosine have a similar shape.
- arginine, lysine and histidine; Alanine, glycine and serine; Phenylalanine, tryptophan and tyrosine are biologically equivalent functions.
- each amino acid is assigned a hydrophobicity index according to its hydrophobicity and charge: isoleucine (+4.5); Valine (+4.2); Leucine (+3.8); Phenylalanine (+2.8); Cysteine / cysteine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamate (-3.5); Glutamine (-3.5); Aspartate (-3.5); Asparagine (-3.5); Lysine (-3.9); And arginine (-4.5).
- the hydrophobic amino acid index is very important in conferring the interactive biological function of proteins. It is well known that substitution with amino acids having similar hydrophobicity indexes can retain similar biological activity. When introducing mutations with reference to the hydrophobicity index, substitutions are made between amino acids which exhibit a hydrophobicity index difference of preferably within ⁇ 2, more preferably within ⁇ 1, even more preferably within ⁇ 0.5.
- the antibody or nucleic acid molecule encoding the same of the present invention is interpreted to include a sequence that exhibits substantial identity with the sequence described in SEQ ID NO.
- the above substantial identity is at least 61% when the sequence of the present invention is aligned as closely as possible with any other sequence, and the aligned sequence is analyzed using algorithms commonly used in the art.
- a sequence that shows homology more preferably 70% homology, even more preferably 80% homology, and most preferably 90% homology. Alignment methods for sequence comparison are known in the art.
- BLAST The NCBI Basic Local Alignment Search Tool (BLAST) is accessible from NBCI and the like and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn and tblastx on the Internet.
- BLSAT is accessible at www.ncbi.nlm.nih.gov/BLAST/. Sequence homology comparisons using this program can be found at www.ncbi.nlm.nih.gov/BLAST/blast_help.html.
- the present invention relates to a nucleic acid encoding the antibody or antigen-binding fragment thereof.
- the nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention can be isolated to recombinantly produce the antibody or antigen-binding fragment thereof.
- the nucleic acid is isolated and inserted into a replicable vector for further cloning (amplification of DNA) or for further expression. Based on this, the present invention relates to a vector comprising the nucleic acid in another aspect.
- Nucleic acid is meant to encompass DNA (gDNA and cDNA) and RNA molecules inclusively, and the nucleotides that are the basic building blocks of nucleic acids include natural nucleotides as well as analogs with modified sugar or base sites. .
- the sequences of nucleic acids encoding heavy and light chain variable regions of the invention can be modified. Such modifications include addition, deletion, or non-conservative or conservative substitutions of nucleotides.
- the nucleic acid encoding the variable region of the antibody or antigen-binding site thereof according to the invention may have a sequence of SEQ ID NO: 18 or SEQ ID NO: 19, wherein the nucleic acid encoding the heavy chain variable region is SEQ ID NO: 18 and the nucleic acid encoding the light chain variable region may be SEQ ID NO: 19.
- Nucleic acids of the invention are also construed to include nucleotide sequences that exhibit substantial identity to the nucleotide sequence. Substantial identity is at least 80% homology when aligning the nucleotide sequence of the present invention with any other sequence as closely as possible and analyzing the aligned sequence using algorithms commonly used in the art. Preferably a nucleotide sequence that exhibits at least 90% homology, most preferably at least 95% homology.
- the DNA encoding the antibody is readily isolated or synthesized using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to the DNA encoding the heavy and light chains of the antibody).
- Many vectors are available.
- Vector components generally include, but are not limited to, one or more of the following: signal sequence, origin of replication, one or more marker genes, enhancer elements, promoters, and transcription termination sequences.
- the term "vector” refers to a plasmid vector as a means for expressing a gene of interest in a host cell; Cosmid vector; Viral vectors such as bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors, and the like.
- the nucleic acid encoding the antibody in the vector is operably linked with a promoter.
- “Operatively linked” means a functional binding between a nucleic acid expression control sequence (eg, an array of promoters, signal sequences, or transcriptional regulator binding sites) and another nucleic acid sequence, whereby the regulatory sequence is the other nucleic acid. To control transcription and / or translation of the sequence.
- a nucleic acid expression control sequence eg, an array of promoters, signal sequences, or transcriptional regulator binding sites
- promoters capable of promoting transcription e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pL ⁇ promoter, pR ⁇ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.
- ribosome binding sites for initiation of translation e.g., amp promoter, recA promoter, SP6 promoter, trp promoter and T7 promoter, etc.
- a promoter derived from the genome of the mammalian cell e.g., a metallothionine promoter, a ⁇ -actin promoter, a human heroglobin promoter and a human muscle creatine promoter
- a mammal Promoters derived from animal viruses e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, tk promoter of HSV, mouse breast tumor virus (MMTV) promoter, LTR promoter of HIV
- a promoter derived from the genome of the mammalian cell e.g., a metallothionine promoter, a ⁇ -actin promoter, a human heroglobin promoter and a human muscle creatine promoter
- a mammal Promoters derived from animal viruses e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter
- the vector may be fused with other sequences to facilitate purification of the antibody expressed therefrom.
- Sequences to be fused include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA).
- Such vectors include antibiotic resistance genes commonly used in the art as selectable markers and include, for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline. There is a resistance gene.
- the present invention relates to a cell transformed with the above-mentioned vector.
- the cells used to produce the antibodies of the invention can be prokaryote, yeast or higher eukaryote cells, but are not limited thereto.
- Bacillus strains such as Escherichia coli, Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g. Pseudomonas putida), Proteus Prokaryotic host cells such as Proteus mirabilis and Staphylococcus (eg, Staphylocus carnosus) can be used.
- Pseudomonas e.g. Pseudomonas putida
- Proteus Prokaryotic host cells such as Proteus mirabilis and Staphylococcus (eg, Staphylocus carnosus) can be used.
- examples of useful host cell lines are COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0 , U20S, or HT1080, but is not limited thereto.
- the present invention (a) culturing the cells; And (b) recovering the antibody or antigen-binding fragment thereof from the cultured cells.
- the cells can be cultured in various media. It can be used as a culture medium without limitation among commercial media. All other necessary supplements known to those skilled in the art may be included at appropriate concentrations. Culture conditions, such as temperature, pH, and the like, are already in use with host cells selected for expression, which will be apparent to those skilled in the art.
- the recovery of the antibody or antigen-binding fragment thereof can be removed by, for example, centrifugation or ultrafiltration, and the resultant can be purified using, for example, affinity chromatography or the like. Further other purification techniques such as anion or cation exchange chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and the like can be used.
- the present invention relates to a composition for preventing or treating cancer, which comprises the antibody as an active ingredient.
- the present invention includes, for example, (a) a pharmaceutically effective amount of an antibody against EGFRvIII or an antigen binding fragment thereof according to the present invention; And (b) it may be a pharmaceutical composition for the prevention or treatment of cancer comprising a pharmaceutically acceptable carrier.
- the present invention also relates to a method for preventing or treating cancer comprising administering to a patient an effective amount necessary for an antibody against EGFRvIII or an antigen-binding fragment thereof.
- composition uses the above-described anti-EGFRvIII antibody or antigen-binding fragment thereof as an active ingredient, the common content between the two is omitted.
- the antibody or antigen-binding fragment thereof of the present invention can bind to EGFRvIII with high affinity to inhibit the migration of cancer cells overexpressing EGFRvIII, and thus can be used for the prevention and treatment of cancer.
- Prevention means any action that inhibits or delays the progression of cancer by administration of a composition according to the invention
- treatment means the inhibition of cancer development, the reduction of cancer or the elimination of cancer.
- Cancer overexpressing EGFRvIII refers to a cancer having a significantly higher level of EGFRvIII on the cancer cell surface compared to non-cancerous cells of the same tissue type.
- Cancer which is a disease applied to the composition is a cancer that overexpresses EGFRvIII, for example glioblastoma, astrocytoma, glioma, neuroblastoma, testicular cancer, colon cancer, melanoma, pancreatic cancer, lung cancer, breast cancer, esophageal cancer, lung cancer, Ovarian cancer, prostate cancer and squamous cell carcinoma.
- EGFRvIII for example glioblastoma, astrocytoma, glioma, neuroblastoma, testicular cancer, colon cancer, melanoma, pancreatic cancer, lung cancer, breast cancer, esophageal cancer, lung cancer, Ovarian cancer, prostate cancer and squamous cell carcinoma.
- the invention is a composition for inhibiting metastasis or invasion of cancer cells comprising an antibody to EGFRvIII or an antigen binding fragment thereof according to the invention.
- the present invention also relates to a method for inhibiting metastasis or invasion of cancer cells by treating an antibody or antigen-binding fragment thereof according to the present invention.
- compositions of the present invention are those commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate , Microcrystalline cellulose, polyvinylpyrrolidone, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- the composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and the like in addition to the above components.
- composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, pulmonary administration and rectal administration Or the like.
- oral compositions should be formulated to coat the active agent or to protect it from degradation in the stomach.
- the pharmaceutical composition may be administered by any device in which the active agent may migrate to the target cell.
- Suitable dosages of the compositions according to the invention vary depending on factors such as the method of formulation, mode of administration, age, weight, sex, morbidity, condition of the patient, food, time of administration, route of administration, rate of excretion and reaction sensitivity, and usually The skilled practitioner can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
- the daily dose of the pharmaceutical composition of the present invention is 0.0001-100 mg / kg.
- pharmaceutically effective amount as used herein means an amount sufficient to prevent or treat cancer.
- compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of extracts, powders, suppositories, powders, granules, tablets, or capsules, and may further include a dispersant or stabilizer.
- compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents.
- the present invention is a composition for diagnosing cancer comprising an antibody against EGFRvIII according to the present invention.
- the present invention also relates to a method for diagnosing cancer by treating an antibody or antigen-binding fragment thereof according to the present invention.
- Cancer can be diagnosed by measuring the level of EGFRvIII expression in a sample via an antibody against EGFRvIII according to the invention.
- Expression levels can be measured according to conventional immunoassay methods, radioimmunoassay using the antibody to EGFRvIII, radioimmunoprecipitation, immunoprecipitation, immunohistochemical staining, enzyme-linked immunosorbant assay (ELISA), capture-ELISA , Inhibition or hardwood analysis, sandwich analysis, flow cytometry, immunofluorescence staining and immunoaffinity purification, but is not limited thereto.
- cancer By analyzing the final signal intensity by the immunoassay process, cancer can be diagnosed. That is, if the protein of the marker of the present invention is expressed high in a biological sample and the signal is stronger than that of the normal biological sample (eg, normal gastric tissue, blood, plasma or serum), the cancer is diagnosed.
- the normal biological sample eg, normal gastric tissue, blood, plasma or serum
- the present invention relates to a cancer diagnostic kit comprising the cancer diagnostic composition.
- the kit according to the present invention comprises an antibody against EGFRvIII according to the present invention, and can diagnose cancer by analyzing a signal indicated by the reaction between the sample and the antibody.
- the signal may include, but is not limited to, an enzyme bound to the antibody, for example, alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase, luciferase or cytochrome P450.
- the substrate for the enzyme is bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), naphthol-AS-B1-phosphate (naphthol) as the substrate.
- BCIP bromochloroindolyl phosphate
- NBT nitro blue tetrazolium
- naphthol-AS-B1-phosphate naphthol
- Chloronaphthol aminoethylcarbazole, diaminobenzidine, D-luciferin, lucigenin when color development reaction substrates such as -AS-B1-phosphate) and enhanced chemifluorescence (ECF) are used, and horse radish peroxidase is used (Bis-N-methylacridinium nitrate), resorphin benzyl ether, luminol, amplex red reagent (10-acetyl-3,7-dihydroxyphenoxazine), HYR (p-phenylenediamine-HCl and pyr ocatechol), TMB (tetramethylbenzidine), ABTS (2,2'-Azine-di [3-ethylbenzthiazoline sulfonate]), o-phenylenediamine (OPD) and naphthol / pyronine, glucose oxidase and t-NBT (nitroblue tetrazolium)
- kits according to the invention may comprise a label which generates a detectable signal, said label comprising a chemical (eg biotin), an enzyme (alkaline phosphatase, ⁇ -galactosidase, horse radish). Peroxidase and cytochrome P450), radioactive materials (eg C14, I125, P32 and S35), fluorescent materials (eg fluorescein), luminescent materials, chemiluminescent and fluorescence resonance energy transfer (FRET) It may include, but is not limited thereto.
- a chemical eg biotin
- an enzyme alkaline phosphatase, ⁇ -galactosidase, horse radish
- Peroxidase and cytochrome P450 cytochrome P450
- radioactive materials eg C14, I125, P32 and S35
- fluorescent materials eg fluorescein
- luminescent materials eg fluorescein
- FRET fluorescence resonance energy transfer
- Measurement of the activity or signal of an enzyme used for cancer diagnosis can be carried out according to various methods known in the art. This allows for quantitative or quantitative analysis of EGFRvIII expression.
- the target antigen protein is adsorbed onto an immunotube, and only the antibody having high binding capacity to the recombinant protein is selected using the biopanning technique.
- recombinant proteins do not cause conformational changes in the structure
- antibodies are selected using proteins expressed on the cell surface where the conformational changes occur in the structure, an antibody that recognizes the change of the antigen may be developed.
- an antibody and an antibody that specifically recognize EGFRvIII were selected by a cell panning technique using glioblastoma patient-derived cells with EGFRvIII.
- the Glioblastoma Multiforme patient-derived cells (437, 448, 464, 626) were sold at the Brain Avatar Tissue Bank of Samsung Medical Center, Institute for Refractory Cancer Research. Received the experiment. Before proceeding with the cell panning technique, mutation and expression levels of EGFRvIII of the patient-derived cells were confirmed by RT-PCR (Reverse Transcription Polymerase Chain Reaction) and western blot method.
- EGFRvIII specific scFv antibody fragments were identified via phage display screening using synthetic scFv phage libraries.
- the phage display screening process is shown in FIG. 2.
- scFv phage library samples were collected in 400 mL of each culture medium (SB / ampicillin /) to recover phagemid vectors containing various human antibody genes introduced into E. coli host ER2537. 2% glucose) and incubated for about 2 hours.
- Host cells incubated with an absorbance of 0.5 at OD 600 were centrifuged at 5,000 g for 20 minutes to remove supernatant, suspended in 400 mL of secondary culture medium (SB / ampicillin), and then 10 12 pfu (plaque forming unit).
- Helper phage (VCSM13) was added and cultured for 1 hour.
- kanamycin antibiotics antibiotic genes introduced into the helper phage
- PEG 8000 polyethylene glycol 8000
- the pellet was precipitated by centrifugation at 15000g, 4 ° C. for 30 minutes and suspended in 1 mL of PBS, and then centrifuged at 10000g, 4 ° C. to obtain only the supernatant to recover the phage library.
- Each sample was diluted and counted in LB / ampicillin solid culture medium again after infection with host cells (ER2537) to count phage recovered from each sublibrary.
- Phage display screening was performed through repeated round panning.
- the counted sub-library was assembled to a level of about 1.0 ⁇ 10 13 pfu, treated with 626 glioblastoma-derived cells knocked down by EGFRvIII antigen, bound for 1 hour at 4 ° C., and bound to 626 patient cells knocked down by EGFRvIII antigen. Only the supernatant not recovered.
- This step removes phages that bind to cell membrane proteins other than EGFRvIII in the antibody phage library to prevent nonspecific binding other than EGFRvIII. After collecting only the supernatant, it was treated with 626 (EGFRvIII +) patient-derived cells and bound at 4 ° C. for 1 hour.
- Cells were washed 5 times using cold complete medium to remove nonspecific binding and then transferred to 37 ° C. for 30 minutes to induce receptor mediated internalization of antigen-antibody complexes.
- the cells were washed with cold PBS and the final washes with 0.1 M Glycine buffer (pH 2.0) to remove uninternalized phage particles bound to the cell surface.
- Neutralization was performed using 2M Tris buffer (pH 8.0), and 0.5 ml of 100 mM TEA (Triethylamine) was added thereto to stand for 10 minutes to lyse cells, and neutralized with 1 mL of 2M Tris buffer (pH 8.0).
- Phage particle amplification was performed by taking 50 ⁇ L of the previous round phage solution stored for subsequent panning cycles. Phage particles recovered by adding helper phage (VCSM13) after incubation in host cells were prepared by PEG precipitation using PEG 8000, and the next round panning was performed in the same manner as the previous round panning. Panning was performed up to four times for 626 (EGFRvIII +) patient-derived cells, and phage display screening results are shown in FIG. 3 and Table 1.
- FIG. 3 and Table 1 Phage particle amplification was performed by taking 50 ⁇ L of the previous round phage solution stored for subsequent panning cycles. Phage particles recovered by adding helper phage (VCSM13) after incubation in host cells were prepared by PEG precipitation using PEG 8000, and the next round panning was performed in the same manner as the previous round panning. Panning was performed up to four times for 626 (EGFRvIII +) patient-derived cells, and phage display screening results are shown in FIG. 3 and Table 1.
- Cell recovery was measured by the ratio of phage particles recovered after cell internalization by binding to 626 cells at each round and phage particles put into cell panning. As the number of patient-derived cell panning cycles increased, the number of recovered phage particles (Output) increased compared to the phage particles (Input) put into 626 cells, thereby confirming the enrichment tendency of target-specific binders. After a total of four cell pannings for 626 patient cells, phage particles recovered in the final round (four rounds) were identified as colonies on LB / ampicillin plates via infection with host cells (ER2537).
- EGFRvIII protein and BSA were coated on 96 well plates at a concentration of 1 ⁇ g / mL, blocked with 3% skim milk powder, and then 25 ⁇ L of the recovered periplasm site was taken to obtain EGFRvIII and BSA coated plates. After addition to the well was bound for 1 hour. After 3-4 times of washing using TBST, HRP conjugated anti-HA antibody (12013819001, Roche Life Science) was combined for 1 hour, and then washed and induced color reaction (TMB substrate) again after OD 450nm The value was measured at.
- TMB substrate induced color reaction
- An scFv candidate group showing binding ability to EGFRvIII was selected by dividing the value of O.D 450 nm obtained by treating any scFv-pIII on a plate coated with EGFRvIII antigen by the value of O.D 450 nm obtained by treating a plate coated with BSA antigen.
- the protein fragment (TOP10F ') was used to express the B4A3 antibody fragment.
- B4A3 scFv protein was prepared by His-tag purification using Ni-NTA bead.
- Cetuximab also known as EGFR antibody, was used as a comparative antibody for the binding pattern. Cetuximab binds to both EGFR and EGFRvIII proteins because it binds to domain III (L2) of the EGFR protein, which is also present in the EGFRvIII protein. In case of Cetuximab, it binds to both EGFR recombinant protein and EGFRvIII recombinant protein but does not bind to LEEKKGNYVVTDHC sequence having EGFRvIII but not EGFR. This is because Cetuximab has an epitope of the L2 domain (aa 310-480) of EGFR. In this domain, EGFR and EGFRvIII are common.
- L2 domain aa 310-480
- the B4A3 antibody binds to the EGFRvIII recombinant protein and LEEKKGNYVVTDHC sequence that only EGFRvIII has, but hardly binds to the EGFR recombinant protein.
- the B4A3 antibody fragment was identified as having epitope LEEKKGNYVVTDHC (SEQ ID NO: 1), amino acids 1-14 of the N-terminal side of the EGFRvIII protein.
- the ELISA method was used to determine the binding capacity according to the concentration of B4A3, an anti-EGFRvIII scFv, against EGFRvIII specific peptides and EGFRvIII recombinant proteins. Based on the results of the three repeated ELISAs, the non-linear regression method was used to determine the approximate target affinity of the B4A3 scFv protein to the EGFRvIII peptide and the EGFRvIII recombinant protein. As a result, it was confirmed that B4A3 scFv showed an approximate target binding capacity of 0.2715 nM on EGFRvIII specific peptide and 2.347 nM on EGFRvIII recombinant protein, respectively.
- NT352T1, 626, 780 Glioblastoma Multiforme patient-derived cells
- EGFRvIII overexpression vector was introduced to make cells expressing only EGFRvIII as cells without EGFR and EGFRvIII to make vIII352T1 cells and continued to be used in subsequent experiments.
- each patient-derived cells were lysed and western blot was performed using 30 ⁇ g of protein lysate. The results are shown in FIG. 8.
- EGFR Rabbit mAb (# 4267, Cell Signaling Technology, Inc.)
- the secondary antibody were Anti-rabbit IgG, HRP-linked Antibody (# 7074, Cell Signaling Technology, Inc.).
- Table 4 shows the results of EGFR and EGFRvIII expression patterns of patient cells.
- NT352T1 patient cells have little expression of EGFR and EGFRvIII.
- vIII352T1 expressing EGFRvIII in NT352T1 patient cells only EGFRvIII protein is expressed and EGFR is not expressed.
- 626 patient cells have both EGFRvIII and EGFR, and 780 patient cells have only EGFR-expressing patient cells and do not have EGFRvIII mutations.
- NT352T1 (EGFR-/ EGFRvIII-), vIII352T1 (EGFR-/ EGFRvIII +), 780 (EGFR + / EGFRvIII-) patient cells were cultured in culture medium (NBA), 5 ⁇ 10 5 cells were prepared in each tube. . After fixed with 4% paraformaldehyde (paraformaldehyde), and then centrifuged and washed once with FACS assay solution. The prepared cells were treated with 1 ⁇ g of B4A3 scFv, an anti-EGFRvIII scFv, and then treated to bind the antibody fragments to the cells through overnight culture at 4 ° C.
- NBA culture medium
- paraformaldehyde paraformaldehyde
- B4A3 EGFRvIII antibody Specificity of the B4A3 EGFRvIII antibody was verified using normal cells expressing EGFR and vIII352T1 cells expressing EGFRvIII.
- the B4A3 antibody used in the FACS experiment was converted to B4A3 human IgG1 form.
- Epidermal cells which are normal cells expressing only EGFR [Primary Epidermal Keratinocytes; Normal, Human, Adult (ATCC ® PCS-200-011 TM)] was purchased from ATCC.
- FACS experiment was conducted in the same manner as mentioned above, the primary antibody was used Cetuximab, B4A3 IgG, the secondary antibody was Alexa Fluor 488 Goat Anti-Human IgG (H + L) Antibody (Life Technologies) It was.
- B4A3 antibody specifically binds to vIII352T1 expressing only EGFRvIII (FIG. 11), and at the same time, showed a minimal binding pattern compared to cetuximab, a control antibody, in normal cells (FIG. 10). Based on the minimal binding capacity to normal cells, B4A3 antibodies are expected to show minimal toxicity to normal cells.
- Cytotoxicity experiments were carried out through the binding of saporin to B4A3 antibody to verify that the B4A3 antibody specifically binds to EGFRvIII / EGFR of target cells and can be applied as an intracellular capability and as an Antibody-Drug Conjugates.
- the binding of saponin, a toxic substance to B4A3 antibody was performed using a ZAP antibody internalization kit (Advanced Targeting Systems, Inc.).
- the toxic substance saporin provided by the ZAP antibody internalization kit is bound to anti-human IgG-IgG, and is bound to a human IgG B4A3 antibody in the form of a secondary antibody.
- NT352T1 patient cells without EGFRvIII expression and vIII352T1 patient cells expressed with EGFRvIII were dispensed at a volume of 90 ⁇ l at 5000 / well in 96 well cell culture plates.
- B4A3 human IgG / saporin conjugated anti-human IgG-IgG conjugate was treated with 10 ⁇ l in cell culture medium, and B4A3 antibody was diluted 1/10 from the highest concentration of 10 nM and subjected to three repeated experiments at 8 concentrations.
- the experiment was performed by adding the saponin alone group and the saporin conjugated anti-human IgG-IgG treated group as a control group, and after 72 hours of treatment with the complex and saporin, cell growth was performed.
- the analysis was performed using the EZ-Cytox kit (WST based Cell Viability / Cytotoxicity Assay Kit), and after incubation in a 37 ° C. CO 2 incubator for 2 hours after treatment with the color reagent, the OD value was analyzed at 450 nm.
- Biacore T200 (GE Healthcare Life Sciences) based on Surface Plasmon Resonance (SPR) was used to quantify the affinity of B4A3 antibodies for EGFR and EGFRvIII.
- the EGFRvIII recombinant protein an antigen used to determine the affinity of an antibody, was prepared by itself, and was added to the extracellular domain amino acid sequence of EGFR based on the EGFR (Entry: P00533) sequence at www.uniprot.org. After removing amino acids 30 to 297, glycine amino acids were added between the sites where 29 and 298 meet, and the Fc tag (IgG1 CH2, Pro110-Lys330 of CH3 domain) was added to the c-terminus (SEQ ID NO: 20, FIG.
- the Biacore T200 is equipped with a Series S Sensor Chip CM5 (GE Healthcare Life Sciences, BR100530) and an Amine Coupling Kit (GE Healthcare Life Sciences, BR100050) and a Human Fab Capture Kit (GE Healthcare Life Sciences, 28-9583-25).
- the Human Fab Capture Antibody was fixed to the surface of the sensor chip.
- B4A3 antibody was diluted to 10 ug / mL in HBS-EP + (GE Healthcare Life Sciences, BR100669) and proceeded for 30 seconds at 30 ⁇ l / min, followed by stabilization, and EGFRvIII antigen was HBS-EP + (GE Healthcare).
- Dilution in Life Sciences, BR100669) was carried out in each cycle to each concentration up to 256nM by increasing the concentration from 0.25nM to 2 times.
- Antigen dosing was performed by diluting HBS-EP + for 30 seconds after binding to 30ul / min, and dissociating HBS-EP + solution for 30 seconds at 30ul / min.
- Glycine 2.0 regeneration buffer (GE Healthcare Life Sciences, BR100355) was used to remove the antibodies and antigens used in the previous step and the next analysis was performed.
- Affinity quantification for EGFR was performed in the same manner as this method, and the affinity of the antibody for antigen was quantified using Biaevaluation software (GE Healthcare Life Sciences).
- the B4A3 antibody hardly binds to EGFR recombinant protein through Sensorgram, and the binding constant to EGFRvIII recombinant protein is found to be 5.661 ⁇ 10 4 (1 / Ms), and the dissociation constant is 2.480 ⁇ 10 -4 (1 / s). Based on this, the affinity of the B4A3 antibody was confirmed to bind to EGFRvIII with an affinity of 4.38 nM (FIG. 13).
- NS07-464T in GBM patient derived cells was used to confirm the in-vivo efficacy of EGFR and EGFRvIII of the B4A3 antibody.
- NS07-464T is a GBM patient derived cell in which EGFR has overexpression / amplification and EGFRvIII mutation.
- NS07-464T was selected as EGFRvIII mutant cells based on the genetic data analyzed by Samsung Medical Center, Inc., and received from the Biobank of Samsung Medical Center, Inc., and was commissioned by RT-PCR and western blot. Expression was confirmed (FIG. 2).
- Human IgG (Sigma, I4506), Cetuximab (Merck), B4A3 antibody
- NS07-464T patient cells made a subcutaneous xenograft model (subcutaneous xenograft model) when the tumor size of about 265mm 3 is formed twice weekly 10mg each A total of four doses were administered at / kg.
- the mice per group were 5 human IgG, 5 Cetuximab groups and 4 B4A3 treatment groups.
- Time from the time when the antibody began to administration is the 13 days, Human IgG group process was formed to a 1426.5 mm 3 tumors, Cetuximab, 13 il Me 1228.5 mm in three sizes this was the control group compared to tumor formation inhibitory ability is formed tumors 14% were confirmed.
- B4A3 antibody formed tumors of 699.5 mm 3 , and the tumor formation inhibitory activity was 51% compared to the control group. This demonstrates the excellent anticancer efficacy in patient-derived cells with the EGFRvIII mutation of B4A3.
- the present invention provides an anti-EGFRvIII antibody and a pharmaceutical use thereof that bind to EGFRvIII expressed on the surface of cancer cells and then internalize into cells.
- the antibodies of the present invention inhibit the invasion and metastasis of cancer cells expressing EGFRvIII.
- the antibody of the present invention can be used for the treatment or diagnosis of cancer, and since EGFRvIII is a molecule that is overexpressed on the surface of cancer cells, the antibody of the present invention can selectively target only cancer cells with minimal effect on normal cells. Can be.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
회차 | Input(cfu/mL) | Output(cfu/mL) | Recovery rate(Output/Input) |
1 | 1E+13 | 4.85E+4 | 4.85E-9 |
2 | 1.13E+13 | 8.96E+4 | 7.93E-9 |
3 | 9.32E+12 | 2.43E+5 | 2.61E-8 |
4 | 6.97E+12 | 1.08E+6 | 1.55E-7 |
중쇄 | 경쇄 | |
CDR1 | GFTFSNYY(서열번호 2) | SSNIGNNY(서열번호 5) |
CDR2 | TSPNGGSK(서열번호 3) | SDS(서열번호 6) |
CDR3 | AKGRRKLRATRFDY(서열번호 4) | ATWDASLSAYV(서열번호 7) |
분석항체 | 항원 | Ka | Kd | KD(nM) |
B4A3 scFv | EGFRvIII peptide(LEEKKGNYVVTDHC) | 3.541e+006 | 0.0009613 | 0.2715 |
rhEGFRvIII protein | 2.739e+006 | 0.006430 | 2.347 |
Cells | EGFRvIII | EGFR |
NT352T1 | - | - |
vIII352T1 | + | - |
626 | + | + |
780 | - | + |
Claims (14)
- EGFRvIII (Epidermal Growth Factor Receptor Variant III)에 결합하는 항체 또는 이의 항원 결합단편으로, 상기 항체 또는 이의 항원 결합단편은 서열번호 1의 서열을 가지는 EGFRvIII의 에피토프에 결합하는 것을 특징으로 하는 항체 또는 이의 항원 결합단편.
- 제1항에 있어서, 서열번호 2의 서열을 가지는 CDR(complementarity determining region)H1, 서열번호 3의 서열을 가지는 CDRH2, 및 서열번호 4의 서열을 가지는 CDRH3을 포함하는 중쇄 가변영역; 및서열번호 5의 서열을 가지는 CDRL1, 서열번호 6의 서열을 가지는 CDRL2, 및 서열번호 7의 서열을 가지는 CDRL3을 포함하는 경쇄 가변영역을 포함하는 것을 특징으로 하는 항체 또는 이의 항원 결합단편.
- 제 1항에 있어서, 서열번호 8 내지 서열번호 15의 서열로 구성된 군에서 선택된 하나 이상의 서열을 가지는 골격 영역 (FR)을 포함하는 것을 특징으로 하는 항체 또는 이의 항원 결합단편.
- 제 1항에 있어서, 서열번호 16의 서열을 가지는 중쇄 가변영역을 포함하는 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 1항에 있어서, 서열번호 17의 서열을 가지는 경쇄 가변영역을 포함하는 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 1항 내지 제 5항 중 어느 한 항의 항체 또는 그의 항원 결합 단편을 코딩하는 핵산.
- 제6항에 있어서, 서열번호 18 또는 서열번호 19의 서열을 가지는 것을 특징으로 하는 핵산.
- 제6항의 핵산을 포함하는 발현 벡터.
- 제8항의 발현 벡터로 형질전환된 세포.
- 다음 단계를 포함하는 제 1항 내지 제 5항 중 어느 한 항의 항체 또는 그의 항원 결합 단편의 제조방법:(a) 제9항의 세포를 배양하는 단계; 및(b) 상기 배양된 세포에서 항체 또는 그의 항원 결합 단편을 회수하는 단계.
- 제 1항 내지 제 5항 중 어느 한 항의 항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물.
- 제 11항에 있어서, 상기 암은 폐암, 대장암, 위암, 신장암, 전립선암, 유방암, 교모세포종, 난소암으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제 1항 내지 제 5항 중 어느 한 항의 항체 또는 그의 항원 결합 단편을 포함하는 암 진단용 조성물.
- 제 13항의 암 진단용 조성물을 포함하는 암 진단용 키트.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201806597XA SG11201806597XA (en) | 2016-02-15 | 2017-02-15 | ANTIBODY AGAINST EGFRvIII AND USE THEREOF |
US16/073,787 US10669340B2 (en) | 2016-02-15 | 2017-02-15 | Antibody against EGFRvIII and use thereof |
AU2017219386A AU2017219386B2 (en) | 2016-02-15 | 2017-02-15 | Antibody against EGFRvIII and use thereof |
CN201780016803.8A CN109476738A (zh) | 2016-02-15 | 2017-02-15 | 抗EGFRvIII的抗体及其用途 |
CA3013584A CA3013584C (en) | 2016-02-15 | 2017-02-15 | Antibody against egfrviii and use thereof |
JP2018542731A JP6795603B2 (ja) | 2016-02-15 | 2017-02-15 | EGFRvIII(Epidermal Growth Factor Receptor Variant III)に対する抗体およびその用途 |
EP17753455.9A EP3418303A4 (en) | 2016-02-15 | 2017-02-15 | ANTI-EGFRVIII ANTIBODIES AND CORRESPONDING USE |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0017118 | 2016-02-15 | ||
KR20160017118 | 2016-02-15 | ||
KR1020170020416A KR101887977B1 (ko) | 2016-02-15 | 2017-02-15 | EGFRvIII (Epidermal Growth Factor Receptor Variant III)에 대한 항체 및 이의 용도 |
KR10-2017-0020416 | 2017-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017142294A1 true WO2017142294A1 (ko) | 2017-08-24 |
Family
ID=59626147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/001623 WO2017142294A1 (ko) | 2016-02-15 | 2017-02-15 | EGFRvIII에 대한 항체 및 이의 용도 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017142294A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114044826A (zh) * | 2021-10-12 | 2022-02-15 | 南京融捷康生物科技有限公司 | 针对EGFRvIII的单域抗体及其衍生蛋白和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523771A (ja) * | 2000-02-25 | 2003-08-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ, アズ レプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改善された細胞傷害性および収率を有する抗EGFRvIIIscFv、それに基づく免疫毒素、ならびにその使用方法 |
US20050222059A1 (en) * | 2002-02-25 | 2005-10-06 | Tang Careen K | Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer |
JP2007297398A (ja) * | 1994-11-28 | 2007-11-15 | Univ Thomas Jefferson | 突然変異上皮成長因子受容体を標的とする試薬および方法 |
KR20120098932A (ko) * | 2003-06-27 | 2012-09-05 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
KR20140091064A (ko) * | 2011-11-16 | 2014-07-18 | 암젠 인크 | 표피 성장 인자 결실 돌연변이체 vⅲ 관련 장애를 치료하는 방법 |
-
2017
- 2017-02-15 WO PCT/KR2017/001623 patent/WO2017142294A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007297398A (ja) * | 1994-11-28 | 2007-11-15 | Univ Thomas Jefferson | 突然変異上皮成長因子受容体を標的とする試薬および方法 |
JP2003523771A (ja) * | 2000-02-25 | 2003-08-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ, アズ レプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改善された細胞傷害性および収率を有する抗EGFRvIIIscFv、それに基づく免疫毒素、ならびにその使用方法 |
US20050222059A1 (en) * | 2002-02-25 | 2005-10-06 | Tang Careen K | Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer |
KR20120098932A (ko) * | 2003-06-27 | 2012-09-05 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
KR20140091064A (ko) * | 2011-11-16 | 2014-07-18 | 암젠 인크 | 표피 성장 인자 결실 돌연변이체 vⅲ 관련 장애를 치료하는 방법 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3418303A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114044826A (zh) * | 2021-10-12 | 2022-02-15 | 南京融捷康生物科技有限公司 | 针对EGFRvIII的单域抗体及其衍生蛋白和应用 |
CN114044826B (zh) * | 2021-10-12 | 2023-11-17 | 南京融捷康生物科技有限公司 | 针对EGFRvIII的单域抗体及其衍生蛋白和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020111913A1 (en) | Anti-4-1bb antibody and use thereof | |
WO2019098682A1 (ko) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 | |
KR102048477B1 (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
WO2015005632A1 (ko) | Dll4와 vegf에 특이적으로 결합하는 신규 이중표적 단백질 및 이의 용도 | |
WO2016013870A1 (ko) | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 | |
WO2019132533A1 (ko) | 항-pd-l1 항체 및 이의 용도 | |
WO2021107566A1 (ko) | C-kit에 대한 항체 및 이의 용도 | |
US10047154B2 (en) | Angiopoietin-2 specific antibodies and uses thereof | |
CN112752580A (zh) | 抗klrg1抗体 | |
WO2016089126A1 (ko) | 뉴로필린 1(Neuropilin 1)에 대한 항체 및 이의 용도 | |
JP2022542574A (ja) | 抗her2/抗4-1bb二重特異性抗体及びその使用 | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
WO2017142294A1 (ko) | EGFRvIII에 대한 항체 및 이의 용도 | |
AU2017219386B2 (en) | Antibody against EGFRvIII and use thereof | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
WO2022216014A1 (ko) | 항-cntn4 항체 및 그의 용도 | |
WO2022025585A1 (ko) | 항-lilrb1 항체 및 그의 용도 | |
WO2017179862A1 (ko) | 안정성이 개선된 her2에 특이적으로 결합하는 항체 | |
KR102119783B1 (ko) | 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 | |
WO2017209553A2 (ko) | 환자 유래 세포를 이용한 항체 스크리닝 방법 | |
WO2023043156A1 (ko) | 항-vegfr2(kdr) 개량 항체 및 이의 용도 | |
WO2023234748A1 (ko) | 항-tigit 항체 및 이의 용도 | |
WO2022244908A1 (ko) | 항-bcam 항체 또는 그의 항원 결합 단편 | |
WO2023136648A1 (ko) | 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2021118246A1 (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17753455 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201806597X Country of ref document: SG Ref document number: 3013584 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018542731 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017753455 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017753455 Country of ref document: EP Effective date: 20180917 |
|
ENP | Entry into the national phase |
Ref document number: 2017219386 Country of ref document: AU Date of ref document: 20170215 Kind code of ref document: A |